Immunogenicity, reactogenicity and safety of 2 doses of an adjuvanted herpes zoster subunit vaccine administered 2, 6 or 12 months apart in older adults: Results of a phase III, randomized, open-label, multicenter study

Vaccine

Volumn 36, Issue 1, 2018, Pages 148-154

  Lal, Himal ^a,d   Poder, Airi ^b   Campora, Laura ^c   Geeraerts, Brecht ^c   Oostvogels, Lidia ^c   Vanden Abeele, Carline ^c   Heineman, Thomas C ^a  

^a GLAXOSMITHKLINE   (United States)

^b Kliiniliste Uuringute Keskus   (Estonia)

^c GSK   (Belgium)

^d PFIZER INC   (United States)

Author keywords

Herpes zoster; HZ su; Immunogenicity; Shingles; Vaccine; Varicella zoster virus

Indexed keywords

IMMUNOGLOBULIN E ANTIBODY; VARICELLA ZOSTER VACCINE; AS01B ADJUVANT; GLYCOPROTEIN E, VARICELLA-ZOSTER VIRUS; LIPID A; SAPONIN; SUBUNIT VACCINE; VIRUS ANTIBODY; VIRUS ENVELOPE PROTEIN;

ADJUVANT THERAPY; ADULT; ADVERSE OUTCOME; AGED; ARTHRALGIA; ARTICLE; BRAIN HEMORRHAGE; CARDIOVASCULAR DISEASE; COHORT ANALYSIS; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; ERYTHEMA; ESTONIA; FATIGUE; FEMALE; HEADACHE; HUMAN; HUMORAL IMMUNITY; IMMUNE RESPONSE; INJECTION SITE PAIN; INJECTION SITE PRURITUS; MALE; MULTICENTER STUDY; MYALGIA; OPEN STUDY; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME; UNITED STATES; VACCINE IMMUNOGENICITY; ANALOGS AND DERIVATIVES; CLINICAL TRIAL; HERPES ZOSTER; IMMUNIZATION; IMMUNOLOGY; MIDDLE AGED; PROCEDURES; VACCINATION; VARICELLA ZOSTER VIRUS;

AGED; ANTIBODIES, VIRAL; ESTONIA; FEMALE; HERPES ZOSTER; HERPES ZOSTER VACCINE; HERPESVIRUS 3, HUMAN; HUMANS; IMMUNIZATION SCHEDULE; IMMUNOGENICITY, VACCINE; LIPID A; MALE; MIDDLE AGED; SAPONINS; UNITED STATES; VACCINATION; VACCINES, SUBUNIT; VIRAL ENVELOPE PROTEINS;

EID: 85034756357     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2017.11.019     Document Type: Article

References (13)

1. Eshleman, E., Shahzad, A., Cohrs, R.J., Varicella zoster virus latency. Future Virol 6 (2011), 341–355.
2. Cohen, J.I., Clinical practice: herpes zoster. N Engl J Med 369 (2013), 255–263.
3. Harpaz, R., Ortega-Sanchez, I.R., Seward, J.F., Prevention of herpes zoster: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 57 (2008), 1–30.
4. Oxman, M.N., Levin, M.J., Johnson, G.R., Schmader, K.E., Straus, S.E., Gelb, L.D., et al. A vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. N Engl J Med 352 (2005), 2271–2284.
5. Chlibek, R., Bayas, J.M., Collins, H., de la Pinta, M.L., Ledent, E., Mols, J.F., et al. Safety and immunogenicity of an AS01-adjuvanted varicella-zoster virus subunit candidate vaccine against herpes zoster in adults ≥50 years of age. J Infect Dis 208 (2013), 1953–1961.
6. Chlibek, R., Smetana, J., Pauksens, K., Rombo, L., Van den Hoek, J.A., Richardus, J.H., et al. Safety and immunogenicity of three different formulations of an adjuvanted varicella-zoster virus subunit candidate vaccine in older adults: a phase II, randomized, controlled study. Vaccine 32 (2014), 1745–1753.
7. Chlibek, R., Pauksens, K., Rombo, L., van Rijckevorsel, G., Richardus, J.H., Plassmann, G., et al. Long-term immunogenicity and safety of an investigational herpes zoster subunit vaccine in older adults. Vaccine 34 (2016), 863–868.
8. Lal, H., Cunningham, A.L., Godeaux, O., Chlibek, R., Diez-Domingo, J., Hwang, S.J., et al. Efficacy of an adjuvanted herpes zoster subunit vaccine in older adults. N Engl J Med 372 (2015), 2087–2096.
9. Cunningham, A.L., Lal, H., Kovac, M., Chlibek, R., Hwang, S.-J., Díez-Domingo, J., et al. Efficacy of the herpes zoster subunit vaccine in adults 70 years of age or older. N Engl J Med 375 (2016), 1019–1032.
10. Weinberg, A., Zhang, J.H., Oxman, M.N., Johnson, G.R., Hayward, A.R., Caulfield, M.J., et al. Varicella-zoster virus-specific immune responses to herpes zoster in elderly participants in a trial of a clinically effective zoster vaccine. J Infect Dis 200 (2009), 1068–1077.
11. Levin, M.J., Oxman, M.N., Zhang, J.H., Johnson, G.R., Stanley, H., Hayward, A.R., et al. Varicella-zoster virus-specific immune responses in elderly recipients of a herpes zoster vaccine. J Infect Dis 197 (2008), 825–835.
12. Gilbert, P.B., Gabriel, E.E., Miao, X., Li, X., Su, S.C., Parrino, J., et al. Fold rise in antibody titers by measured by glycoprotein-based enzyme-linked immunosorbent assay is an excellent correlate of protection for a herpes zoster vaccine, demonstrated via the vaccine efficacy curve. J Infect Dis 210 (2014), 1573–1581.
13. Lal, H., Zahaf, T., Heineman, T.C., Safety and immunogenicity of an AS01-adjuvanted varicella zoster virus subunit candidate vaccine (HZ/su): a phase-I, open-label study in Japanese adults. Hum Vaccin Immunother 9 (2013), 1425–1429.